AIM ImmunoTech, Inc. (AIM)

0.4898 -0.06 (-10.16%) USD  |  NYAM  |  Apr 20, 11:28
More

AIM ImmunoTech SG&A Expense (Quarterly) : 1.87M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for AIM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Agenus, Inc. 12.30M
Curis, Inc. 2.883M
Plus Therapeutics, Inc. 4.168M
Windtree Therapeutics, Inc. 1.855M
Halozyme Therapeutics, Inc. 77.03M